Patents Assigned to MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH
-
Patent number: 10752697Abstract: The present invention relates to an antibody specifically binding to glypican 3 (GPC3), a nucleic acid encoding the antibody, a vector and a host cell containing the nucleic acid, a method of preparing the antibody, and a pharmaceutical composition for treating cancer or tumor, containing the antibody as an active ingredient. The antibody specifically binding to glypican 3 according to the present invention may be effectively used to treat cancer or tumor, particularly, hepatocellular carcinoma due to high affinity and specificity to glypican 3.Type: GrantFiled: October 27, 2016Date of Patent: August 25, 2020Assignee: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCHInventors: Jae Chan Park, Kisu Kim, Mijung Lee, Eun-Hee Lee, Dong-Sik Kim, Eun Jung Song, Sujeong Kim, Hyung-Kwon Lim, Kyuhyun Lee, Jongwha Won, Soongyu Choi, Young Seoub Park
-
Publication number: 20200262928Abstract: The present invention relates to an anti-MSLN antibody and a pharmaceutical composition for cancer treatment comprising same. The anti-MSLN antibody according to the present invention has high affinity and specificity for MSLN and thus can be effectively used in cancer prevention or treatment.Type: ApplicationFiled: October 22, 2018Publication date: August 20, 2020Applicants: GREEN CROSS CORPORATION, MOGAM INSTITUTE FOR BIOMEDICAL RESEARCHInventors: Ki Su KIM, Jung Hong JEONG, Dong Sik KIM, Yang Mi LIM, Yong Yea PARK, Hyung Kwon LIM, Jong Wha WON
-
Publication number: 20200109196Abstract: The present invention provides anti-CEACAM1 antibodies with improved binding abilities specific to CEACAM1, and a use thereof. Anti-CEACAM1 antibodies according to the present invention exhibit superior binding abilities specific to CEACAM1, and also activate the anti-cancer immune functions of cytotoxic T cells and natural killer cells, and thus, each one of them can be effectively used as an anti-cancer agent and a composition for treating cancer.Type: ApplicationFiled: March 23, 2018Publication date: April 9, 2020Applicants: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH, GREEN CROSS CORPORATIONInventors: So-Young EUN, Miyoung OH, Hye-Young PARK, Mijung LEE, Aerin YOON, Hye In YUM, Hyemi NAM, Eunhee LEE, Jongwha WON
-
Publication number: 20190330311Abstract: A chimera protein according to the present application has a significantly increased in vivo half-life when administered because of a vWF domain coupled to FVIII, such that when used as a hemophilia A therapeutic agent, convenience for patients can be increased and medical expenses can be reduced.Type: ApplicationFiled: June 23, 2017Publication date: October 31, 2019Applicant: Mogam Institute for Biomedical ResearchInventors: Injae OH, Seung-Hoon LEE, Eui-Cheol JO, Mee Sook OH, Jae Hwan RYU, Yong Jae KIM, So Ra KIM, Jin-hyun PARK
-
Publication number: 20190328868Abstract: The present invention relates to a herpes zoster vaccine composition, which comprises glycoprotein E of Varicella zoster virus, a glucopyranosyl lipid adjuvant, and a metabolic oil, and selectively increases a cell-mediated immune reaction without having disadvantages of attenuated live vaccines, thereby exhibit high safety and a high preventive effect against herpes zoster.Type: ApplicationFiled: December 20, 2017Publication date: October 31, 2019Applicants: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH, INFECTIOUS DISEASE RESEARCH INSTITUTEInventors: Hyo Jung NAM, Eun Mi KIM, Duck Hyang SHIN, Steven G. REED, Kang Il YOO, Sung Jun HONG
-
Publication number: 20190194618Abstract: A method for determining immunogenicity of a protein agent. The method includes constructing a library of peripheral blood mononuclear cells having various HLA-DRB1 genotypes; culturing peripheral blood mononuclear cell CD14+ monocyte-derived immature dendritic cells for each genotype in a medium containing a protein to be measured, GM-CSF, IL-4, TNF-?, IL-1?, IL-6 and PGF2 to prepare mature dendritic cells; removing CD8+ T cells from the peripheral blood mononuclear cells for each genotype to prepare CD8+ T cell-free peripheral blood mononuclear cells; co-culturing the mature dendritic cells and the CD8+ T cell-free peripheral blood mononuclear cells at a cell count ratio of approximately 1:5 to 1:20; and quantifying the CD4+ T cells proliferated by co-cultivation per genotype.Type: ApplicationFiled: August 31, 2017Publication date: June 27, 2019Applicant: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCHInventors: Ok Jae LIM, Duck Hyang SHIN
-
Publication number: 20190135884Abstract: A composition and a method for treating a bone and cartilage disease (including, but not limited to, cartilage disorder and cartilage damage such as injury to the articular cartilage, osteoarthritis, costochondritis, herniation, achondroplasia, relapsing polychondritis, benign or non-cancerous tumors, or malignant or cancerous tumors) are disclosed, wherein the compositions comprise chimeric polypeptides having TGF-beta activity.Type: ApplicationFiled: May 31, 2017Publication date: May 9, 2019Applicant: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCHInventors: Sen Yon CHOE, Innokentiy MASLENNIKOV, Yong Chul KIM, Na Young PARK
-
Publication number: 20190135885Abstract: A composition and a method for treating a liver disease (including, but not limited to, non-alcoholic fatty liver disease, liver fibrosis and hepatic inflammation) are disclosed. The composition comprises a chimeric polypeptide having TGF-beta activity. The method includes administering an effective amount of the composition to a subject in need of treating a liver disease.Type: ApplicationFiled: May 31, 2017Publication date: May 9, 2019Applicant: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCHInventors: Sen yon CHOE, Innokentiy MASLENNIKOV, Yong Chul KIM, Jung Yoon CHOI
-
Publication number: 20190119388Abstract: The present invention provides a pharmaceutical composition for inhibiting the metastasis of cancer, comprising, as an active ingredient, an antibody that specifically binds to an epidermal growth factor receptor, and a method for inhibiting the metastasis of cancer using the composition. The composition or the method is effective in inhibiting the invasion of various gastric cancer cell lines induced by EGFR ligands. Therefore, the pharmaceutical composition can be usefully used for inhibiting the metastasis of cancer.Type: ApplicationFiled: April 27, 2016Publication date: April 25, 2019Applicants: GREEN CROSS CORPORATION, MOGAM INSTITUTE FOR BIOMEDICAL RESEARCHInventors: Jong-hwa WON, Yangmi LIM, Min-Kyu HUR
-
Patent number: 10266607Abstract: The present invention relates to an antibody that binds specifically to a tissue factor pathway inhibitor (TFPI), a nucleic acid encoding the antibody, a vector comprising the nucleic acid, a host cell transformed with the vector, a method for producing the antibody, and a pharmaceutical composition for treating hemophilia, which comprises the antibody as an active ingredient. The antibody of the present invention, which binds specifically to TFPI, can activate the extrinsic pathway of blood coagulation by inhibiting TFPI. Thus, the antibody of the present invention can be effectively used for the treatment of antibody-induced hemophilia patients and for the prevention of blood coagulation disease in hemophilia-A or hemophilia-B patients.Type: GrantFiled: December 29, 2015Date of Patent: April 23, 2019Assignee: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCHInventors: Dong-Sik Kim, Mi Jung Lee, Jae Chan Park, Sumin Lee, Heechun Kwak, SungHo Hwang, Hyung-Kwon Lim, Kisu Kim, Young Seoub Park, Junhong Jeong, Ki Joon Cho
-
Publication number: 20180346588Abstract: The present invention relates to an antibody specifically bound to mesothelin (MSLN), a nucleic acid encoding the antibody, a vector and a host cell including the nucleic acid, a method for producing the antibody, and a pharmaceutical composition for treating cancer or tumor including the antibody as an active ingredient. The antibody specifically bound to the mesothelin according to the present invention has high affinity and specificity to an antigen, such that it is possible to develop an antibody effectively usable for treatment or diagnosis of cancer or tumor diseases.Type: ApplicationFiled: September 23, 2016Publication date: December 6, 2018Applicants: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH, GREEN CROSS CORPORATIONInventors: Dong-Sik KIM, Eun Jung SONG, Mijung LEE, Eun-Hee LEE, Miyoung OH, Jae Chan PARK, Kisu KIM, Sujeong KIM, Hyung-Kwon LIM, Kyuhyun LEE, Jongwha WON, Soongyu CHOI, Young Seoub PARK
-
Publication number: 20180168134Abstract: A transgenic mouse expressing inactivated human iduronate-2-sulphatase (IDS) and a method for improving agents for treating Hunter syndrome using the transgenic mouse are provided. The transgenic mouse expressing the inactivated human IDS, which has immune tolerance to IDS, does not cause an immune response to IDS which is an active component of the agents for treating Hunter syndrome, and thus the transgenic mouse may be effectively used to identify immunogenic factors other than the immunogenicity of the protein components of the agents.Type: ApplicationFiled: December 20, 2017Publication date: June 21, 2018Applicant: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCHInventors: Chihwa KIM, Jaehyeon LEE, Eui-Cheol JO, Jung-Seob KIM
-
Publication number: 20180030151Abstract: The present invention relates to an antibody that binds specifically to a tissue factor pathway inhibitor (TFPI), a nucleic acid encoding the antibody, a vector comprising the nucleic acid, a host cell transformed with the vector, a method for producing the antibody, and a pharmaceutical composition for treating hemophilia, which comprises the antibody as an active ingredient. The antibody of the present invention, which binds specifically to TFPI, can activate the extrinsic pathway of blood coagulation by inhibiting TFPI. Thus, the antibody of the present invention can be effectively used for the treatment of antibody-induced hemophilia patients and for the prevention of blood coagulation disease in hemophilia-A or hemophilia-B patients.Type: ApplicationFiled: December 29, 2015Publication date: February 1, 2018Applicant: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCHInventors: Dong-Sik KIM, Mi Jung LEE, Jae Chan PARK, Sumin LEE, Heechun KWAK, SungHo HWANG, Hyung-Kwon LIM, Kisu KIM, Young Seoub PARK, Junhong JEONG, Ki Joon CHO
-
Publication number: 20170319621Abstract: The present invention relates to a method for producing natural killer cells using T cells, and more particularly, to a method for producing natural killer cells, which comprises culturing seed cells using CD4(+) T cells as feeder cells. The method for producing natural killer cells using T cells according to the present invention is a method capable of producing natural killer cells by selectively proliferating only natural killer cells from a small amount of seed cells while maintaining the high killing activity of the natural killer cells. The method of the present invention can produce a large amount of natural killer cells that can be frozen, and thus is useful for commercialization of cell therapeutic agents.Type: ApplicationFiled: November 25, 2015Publication date: November 9, 2017Applicants: GREEN CROSS LAB CELL CORPORATION, MOGAM INSTITUTE FOR BIOMEDICAL RESEARCHInventors: Bo Kyung MIN, Hana CHOI, Yu Kyeong HWANG